

Vaccines for Dengue Viruses

Ref. No. E-273-2011

Keywords: Vaccines, Infectious Diseases, Monoclonal/Polyclonal Antibody Fragment, dengue, hemorrhagic fever, immunization

Summary:

The National Cancer Institute's Cancer and Inflammation Program seeks parties interested in licensing or collaborative research to further co-develop fully human monoclonal antibodies as possible therapeutics and prophylactics, as well as a template for a Dengue vaccine.

Description of Technology:

Dengue viruses cause dengue outbreaks and major epidemics in most tropical and subtropical areas where *Aedes albopictus* and *Aedes aegypti* mosquitoes are abundant. Among the arthropod-borne flaviviruses, the four dengue virus serotypes, dengue type 1 virus (DENV-1), dengue type 2 virus (DENV-2), dengue type 3 virus (DENV-3), and dengue type 4 virus (DENV-4) are most important in terms of human morbidity and geographic distribution. A safe and effective vaccine against dengue is currently not available. Passive immunization with monoclonal antibodies from non-human primates or humans represents a possible alternative to vaccines for prevention of illness caused by dengue virus. Researchers at NCI's [Cancer and Inflammation Program](#) developed fully human monoclonal antibodies that bind and neutralize dengue type 1, 2, 3 and 4 viruses, as well as fragments of such antibodies and nucleic acids encoding the antibodies of the technology, and prophylactic, therapeutic and diagnostic methods employing the antibodies and nucleic acids of the invention.

Potential Commercial Applications:

- Prophylaxis/therapy against dengue serotypes 1, 2, 3, and 4;
- Dengue diagnostics.

Competitive Advantages:

- Antibodies are cross-reactive with all four serotypes of dengue;
- Antibodies are fully human.

Inventor(s):

[Dimitar S. Dimitrov](#) (NCI), [Zhongyu Zhu](#) (NCI)

Development Stage:

-- Discovery (Lead Identification)

Publications:

- Puri V et al. PMID: [23765162](#)

Patent Status:

US (filed): PCT/US13/40966 filed 14 May 2013

Foreign (filed): PCT/US13/40966 filed 14 May 2013

Contact Information:

Co-Development Opportunities:

John D. Hewes, Ph.D.

NCI Technology Transfer Center

Phone: 240-276-5515

E-mail: john.hewes@nih.gov

Related Opportunities:

E-066-2003